Company intelligence / Profile preview

PharmAbcine

Ownership: Private
Development stage: Phase 1

Overview

PharmAbcine is a clinical-stage biotech developing next-generation antibody therapeutics. Its lead asset, Olinvacimab, is in Phase II trials for mTNBC in combination with pembrolizumab and has shown a promising objective response rate of 50% and disease control rate of 67% with favorable safety. PMC‑403 is in Phase I for neovascular AMD and preclinical/early clinical studies for rare vascular diseases. PMC‑309 targets VISTA as an immune checkpoint inhibitor and is currently in early-phase trials for solid tumors[6][8][9].

Therapeutic areas: OphthalmologyOncologyRare Diseases
Modalities: Monoclonal antibodies (mAbs)Bispecific antibodiesIgG-based therapeuticsAntibody-drug conjugates (potential, based on pipeline diversity)
Industry: Biotech

Drug pipeline

13 assets

olinvacimab

12 more assets in the full pipeline.

Request access →

Partnerships

MSD/Merck & Co.: Collaboration on combination trials with pembrolizumab/Keytruda.Novartis and OrbiMed were early investors at founding.[4]

Beyond the preview

Go deeper on PharmAbcine.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PharmAbcine.

Explore the full profile